CS
CNCE

Credit Suisse’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Credit Suisse’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-20,255
Closed -$244K – 4275
2019
Q1 		$244K Buy
20,255
+750
+4% +$11.1K ﹤0.01% 3698
2018
Q4 		$244K Buy
19,505
+988
+5% +$13.6K ﹤0.01% 3600
2018
Q3 		$274K Sell
18,517
-4,125
-18% -$64.9K ﹤0.01% 3564
2018
Q2 		$381K Sell
22,642
-89
-0.4% -$1.73K ﹤0.01% 3550
2018
Q1 		$520K Sell
22,731
-686
-3% -$15.3K ﹤0.01% 3342
2017
Q4 		$605K Buy
23,417
+9,726
+71% +$196K ﹤0.01% 3335
2017
Q3 		$202K Buy
+13,691
New +$199K ﹤0.01% 3928
2017
Q2 		– Sell
-29,327
Closed -$500K – 4004
2017
Q1 		$500K Sell
29,327
-3,865
-12% -$46.4K ﹤0.01% 3283
2016
Q4 		$341K Sell
33,192
-4,262
-11% -$39K ﹤0.01% 3604
2016
Q3 		$378K Buy
37,454
+2,560
+7% +$28K ﹤0.01% 3560
2016
Q2 		$392K Buy
34,894
+13,839
+66% +$176K ﹤0.01% 3559
2016
Q1 		$287K Buy
21,055
+6,570
+45% +$94.6K ﹤0.01% 3532
2015
Q4 		$275K Sell
14,485
-23,930
-62% -$520K ﹤0.01% 3732
2015
Q3 		$721K Buy
38,415
+11,244
+41% +$191K ﹤0.01% 3120
2015
Q2 		$404K Sell
27,171
-36,582
-57% -$557K ﹤0.01% 3853
2015
Q1 		$965K Buy
63,753
+39,094
+159% +$545K ﹤0.01% 3000
2014
Q4 		$329K Buy
24,659
+14,472
+142% +$187K ﹤0.01% 3996
2014
Q3 		$128K Buy
+10,187
New +$98.8K ﹤0.01% 4266
2014
Q2 		– Sell
-12,910
Closed -$174K – 4846
2014
Q1 		$174K Buy
+12,910
New +$182K ﹤0.01% 4399

Other funds holding CNCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Credit Suisse's CNCE Position: Q2 2019 in Review

Credit Suisse sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2019, closing a stake of 20,255 shares — an estimated $244K sold.

Credit Suisse first reported a position in CNCE in Q1 2014 and held it in 19 quarters. The position peaked at $965K in Q1 2015. 87 funds tracked by Wall St. Rank hold CNCE as of Q2 2019.

  • Credit Suisse reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Credit Suisse sold 20,255 Concert Pharmaceuticals, Inc. shares in Q2 2019, an estimated $244K.
  • Credit Suisse first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 19 quarters.
  • Credit Suisse's Concert Pharmaceuticals, Inc. position peaked at $965K in Q1 2015.
  • 87 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2019.

Based on Credit Suisse's 13F filing for Q2 2019, filed 14 Aug 2019.